Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Tacere Reacquires Asian Rights to Novel Hepatitis C Treatment

publication date: Feb 4, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Tacere Therapeutics of California said it reacquired Asian rights to its RNA interference candidates for hepatitis C infection from Oncolys BioPharma in Japan. Tacere announced the move immediately after Pfizer exercised its option to continue R&D of the company’s RNAi hepatitis drugs for ex-Asian markets. More details....

Stock Symbol: (NYSE: PFE)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...